|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Drug** | **Dose** | **Drug Type** | **Trial** | **N** | **N for Model** | **Inclusion Criteria** | **Pubmed ID** |
| Ustekinumab | IV: 6 mg/kg at 0 weeks IV: 130 mg at 0 weeks\* | Anti-IL12p40 | NCT01369342 | 209, 209 | 1127 | anti-TNF naïve, CDAI 220 - 450 and either CRP > 0.3 mg/L, fecal calprotectin > 250 mg/kg, or endoscopic evidence of inflammation | 27959607 |
| MEDI2070 | IV: 700 mg at 0, 4 weeks then 210 mg SC every 4 weeks from week 12 | Anti-IL23A | NCT01714726 | 59 | 246 | CDAI 220 - 450 and either CRP ≥ 5 mg/L, calprotectin ≥ 250 ug/g, or endoscpoic findings of at least 3 non-anastomotic ulcerations | 28390867 |
| Risankizumab | IV: 200 mg at 0, 4, and 8 weeks IV: 600 mg at 0, 4, and 8 weeks\* | Anti-IL23A | NCT02031276 | 41, 41 | 133 | CDAI 220 - 450 and CDEIS of at least 7 | 28411872 |
| Infliximab | IV: 5 mg/kg at 0, 2, and 6 weeks | Anti-TNFα |  | 22 | 144 | CDAI range 153 - 337 | 21461070 |
| IV: 5 mg/kg at 0 and 8 weeks | Anti-TNFα |  | 15\*\*\*\* |  | CD patients with acute flare, chronic active disease, or rapid reoccurrence of disease postoperatively | 18484671 |
| IV: 5 mg/kg at 0, 2, and 6 weeks\*\*\* | Anti-TNFα | ACCENT 1 | 580 |  | CDAI 220-400 | 21741088 |
| PF-04236921 | SC: 10 mg, 50 mg\*\*, or 200 mg at 0, 4 weeks | Anti-IL6 | NCT01287897 | 68, 71, 40 | 286 | CDAI 220 - 450 with CRP ≥ 5 mg/L and ulceration demonstrated by colonoscopy | 29247068 |
|  |  |  |  |  |  |  |  |
| \*These cases are shown in supplementary | | |  |  |  |  |  |
| \*\* Baseline Population shown is chosen from 50 mg group | | | |  |  |  |  |
| \*\*\* Concentration is the one show in Baseline Population figure | | | |  |  |  |  |
| \*\*\*\* In the study one patient received adalimumab induction dose 80 mg s.c. at week 0, followed by 40 mg s.c. every other week until week 8 | | | | | | | |
|  |  |  |  |  |  |  |  |